Gamma delta T cells are a novel immunotherapy for AML. Recent review from our group https://t.co/v8MgGKyeLv We have clinical trials w Aza Ven & gd2T cell activating ICT01 for Newly Dx AML, & allogeneic gd1T cells for R/R #AML https://t.co/66peT9TKvA
https://t.co/LGMVN5oyyl
#leusm
Applications for the Fundamental Research Career Development Awards open January 3. Up to three annual awards of up to $50,000 USD will be given. Remember, applicants must also submit and abstract to #ISTH2024. Learn more: https://t.co/Bp1580zDNY
It is known that B-ALL with KMT2A rearrangement may undergo lineage switch after therapy. See below a KMT2A-R B-ALL case switching to an AML (CD34+ HLA-DR+) after treatment, then switching to a monocytic leukemia (CD14+ CD64+/CD34- HLA-DR-) 2 years later
#hemepath@ICCS_Education
Congratulations to the SSC Grants awardees, including @AJTafur. This is an annual program that provides funding to support and advance state-of-the-art projects from the subcommittees of the ISTH Scientific and Standardization Committee (SSC). Read more: https://t.co/St3ukO3P2y
Our “vaccine + CAR T -> antigen spreading” story is finally online🥳 —an effective approach to enhance CAR T therapy against solid tumors with antigen heterogeneity. We are recruiting motivated postdocs to continue this exciting research! Please spread the words 🥳
📣Publication alert: finally published in @TheLancet , the ALIFE2 trial. So thankful to all women who participated and all colleagues who joined the study. LMWH does NOT improve live birth in women with #thrombophilia and #recurrent miscarriage.
https://t.co/PrbO0rrX6H
American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing | Blood Advances | American Society of Hematology https://t.co/EIEijhZjbB
Considering we are paying a fortune for old drugs like lenalidomide and pomalidomide due to our broken patent and pricing system, teclistamab is a bargain. #MedTwitter